led to the development of novel SMO inhibitors based on acylguanidine or acylthiourea scaffolds, which specifically target SMO in melanoma cells, thereby reducing Gli1 expression, inducing DNA damage and apoptosis, and inhibiting the self-renewal of MSCs (166). The gene discussed is GLI1; the disease is melanoma.